Soligenix Inc. (NASDAQ: SNGX) is advancing a novel therapeutic approach for cutaneous T-cell lymphoma through its development of HyBryte, also known as synthetic hypericin. Cutaneous T-cell lymphoma is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages, creating significant challenges for patients and healthcare providers within a challenging diagnostic and treatment landscape.
HyBryte represents a visible light-activated photodynamic therapy designed specifically for the treatment of early-stage CTCL. Unlike traditional ultraviolet-based phototherapies that can carry long-term safety risks with cumulative exposure, HyBryte is activated by visible light in the red-yellow spectrum. This mechanism allows for targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue, potentially addressing critical safety concerns associated with existing therapies.
Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte as a novel photodynamic therapy utilizing safe visible light. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's development programs in this business segment also include expansion of synthetic hypericin into psoriasis, the company's first-in-class innate defense regulator technology, dusquetide for the treatment of inflammatory diseases including oral mucositis in head and neck cancer, and additional applications in Behçet's disease.
The company maintains a Public Health Solutions business segment that includes development programs for RiVax, its ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola and CiVax, the company's vaccine candidate for the prevention of COVID-19. The development of Soligenix's vaccine programs incorporates the use of its proprietary heat stabilization platform technology known as ThermoVax. This business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
For further information about the company's developments, visit https://www.Soligenix.com. Additional news and updates relating to SNGX are available through specialized financial communications platforms that provide wire-grade press release syndication for public companies and the investment community.
